Largest health center in Italy uses SOPHiA DDM™ Platform on Microsoft
Azure to expand data-driven medicine capabilities while ensuring
accuracy and security
BOSTON and ROLLE, Switzerland, Nov. 28,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company in the healthcare space and a
leader in data-driven medicine, today announced the expansion
of its relationship with the Città della Salute e della Scienza di
Torino located in Turin, Italy. The hospital, which used SOPHiA
GENETICS after a public tender in 2021 to optimize workflows and
support research in the areas of hereditary cancer, neurological
disorders, solid tumors, hematology and rare disease, will further
expand its usage of the SOPHiA DDM™ Platform to support research on
homologous recombination repair (HRR) biomarkers that indicate
treatment options for ovarian, prostate, breast and pancreatic
cancers.
Città della Salute e della Scienza di Torino is part of one of the largest
university hospitals and health systems in Europe. As such, the institution cares for
thousands of people each year and is responsible for the efficient,
accurate and secure analysis of a vast amount of genomic data.
"The ability to partner with a technology provider that can help
efficiently decipher the expansive amount of data from raw next
generation sequencing (NGS) data – and guarantee security of such
data – is of paramount importance to our institution," said Dr.
Barbara Pasini, Head of the Medical
Genetics Unit, Città della Salute e della Scienza di Torino. "The SOPHiA DDM™ Platform, which
leverages the cloud infrastructure of Microsoft Azure, answers our
needs by providing the secure analysis of all data coupled with
simplified insights."
NGS is helping to revolutionize the research of several cancers
and rare diseases, yet it yields extremely large and complex
datasets for analysis. The Microsoft Azure-powered
SOPHiA DDM™ Platform uses artificial intelligence and
machine learning with patented technologies to streamline the
analysis of raw NGS data and generate biologically actionable
insights, which can speed the research process and ultimately lead
to better health outcomes.
SOPHiA GENETICS has worked with Microsoft to further the
democratization of data-driven medicine. Using the secure,
cloud-based infrastructure of Microsoft Azure, SOPHiA GENETICS
offers a solution via the SOPHiA DDM™ Platform that helps break the
data silos and facilitate data-sharing and research
advancements.
"The SOPHiA DDM™ Platform has helped us to optimize our research
in specific cancer types, such as the recently added analysis on
ovarian and prostate tumors, that may contain somatic BRCA1 and
BRCA2 gene variants. The platform has enabled our researchers
analyzing tumor samples to more quickly come to data-driven
conclusions and move towards the practice of precision medicine,"
said Dr. Francia di Celle and Dr.
Bonello, of the Molecular Pathology Laboratory, Città della Salute
e della Scienza di Torino.
"The partnership between SOPHiA GENETICS and Microsoft provides
clients such as Città della Salute e della Scienza di
Torino with convenience and flexibility to implement the
technology solutions necessary to suit their needs, while ensuring
peace of mind that their data is secure," said Kevin Puylaert,
Managing Director, EMEA, SOPHiA GENETICS. "We are excited to be
expanding our work with organizations that recognize the innovative
power of precision medicine and the elevated standard of care it
can provide to patients."
"Together we're not only enhancing operational efficiency but
also unveiling unprecedented potential within medical and genomic
data landscapes by leveraging Azure for data ingestion and data
management in the SOPHiA DDM™ Platform. This new era of cooperation
allows healthcare providers to bolster their capabilities in
managing multimodal data, which paves the way for deriving profound
insights conducive to enhanced patient care," said Elena Bonfiglioli, General Manager, WW
Healthcare, Global Pharma and Life Sciences, Microsoft. "Microsoft
is pleased to continue supporting SOPHiA GENETICS' mission to
democratize data-driven medicine by providing secure and scalable
cloud infrastructure."
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on X, LinkedIn, Facebook,
and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native software company
in the healthcare space dedicated to establishing the practice of
data-driven medicine as the standard of care and for life sciences
research. It is the creator of the SOPHiA DDM™ Platform, a
cloud-native platform capable of analyzing data and generating
insights from complex multimodal data sets and different diagnostic
modalities. The SOPHiA DDM™ Platform and related solutions,
products and services are currently used by a broad network of
hospital, laboratory, and biopharma institutions
globally. For more information,
visit SOPHiAGENETICS.COM,
or connect
on X, LinkedIn, Facebook,
and Instagram. Where others
see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA DDM™ miniHRS Solution is available as a CE-IVD product
for In Vitro Diagnostic Use in Europe and Turkey. The information in this
press release is about products that may or may not be available in
different countries and, if applicable, may or may not have
received approval or market clearance by a governmental regulatory
body for different indications for use. Please contact
support@sophiagenetics.com to obtain the appropriate product
information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-expands-relationship-with-citta-della-salute-e-della-scienza-di-torino-301998512.html
SOURCE SOPHiA GENETICS